Oppenheimer and H.C. Wainwright reiterated Outperform and Buy ratings for Ionis Pharmaceuticals on September 24, 2026. H.C. Wainwright maintained a $100 price target. Oppenheimer held its price target at $85.00.
The company announced positive late-stage clinical trial results on September 22 and 23. These trials evaluated ulefnersen for a rare ALS subtype and sefaxersen for IgA nephropathy. Analysts view the data as validation for Ionis’s RNA-targeted technology platform.
Sefaxersen is developed in partnership with Roche. The results may trigger regulatory discussions before final two-year kidney-function data is available. These developments strengthen analyst confidence in the company’s neurology and renal pipelines.